Gainers

• Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday's pre-market session. The company's market cap stands at $20.9 million.
• Jupiter Neurosciences (NASDAQ:JUNS) shares rose 64.57% to $8.51. The market value of their outstanding shares is at $3.9 million.
• Gossamer Bio (NASDAQ:GOSS) shares rose 31.55% to $0.21. The company's market cap stands at $76.9 million.
• Addex Therapeutics (NASDAQ:ADXN) shares rose 26.91% to $5.8. The company's market cap stands at $5.6 million.
• BioVie (NASDAQ:BIVI) stock rose 17.74% to $2.19. The company's market cap stands at $15.7 million.
• Cypherpunk Technologies (NASDAQ:CYPH) shares rose 12.6% to $1.34. The market value of their outstanding shares is at $128.2 million.

Losers

• iSpecimen (NASDAQ:ISPC) shares decreased by 22.9% to $1.75 during Friday's pre-market session. The company's market cap stands at $5.7 million.
• Apimeds Pharmaceuticals (AMEX:APUS) stock decreased by 14.36% to $3.76. The market value of their outstanding shares is at $6.6 million.
• Profusa (NASDAQ:PFSA) stock declined by 9.12% to $6.88. The company's market cap stands at $4.0 million. As per the news, the Q2 earnings report came out yesterday.
• ZeroStack (NASDAQ:ZSTK) shares decreased by 7.98% to $5.42. The market value of their outstanding shares is at $14.2 million.
• Telix Pharmaceuticals (NASDAQ:TLX) stock declined by 7.66% to $11.47. The company's market cap stands at $4.1 billion.
• Aveanna Healthcare Hldgs (NASDAQ:AVAH) stock fell 7.1% to $12.05. The company's market cap stands at $2.8 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.